A Phase 4 interventional study of Paliperidone Extended Release (ER) in Schizophrenia, sponsored by Janssen-Cilag Farmaceutica Ltda.. Completed at 11 sites in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-11-20.
Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 49th largest by enrollment, is one of 13 that started in 2008, is one of 42 in phase 4, and was the 50th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag Farmaceutica Ltda., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Farmaceutica Ltda. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 72nd largest by enrollment of the 176 interventional ones that give a count, is one of 17 that started in 2008, is one of 47 in phase 4, and was the 126th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate effectiveness, tolerability (how well a participant can stand a particular medicine or treatment), and safety of flexible-dose of paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), previously taking risperidone (an antipsychotic), but who are not satisfied with their treatment.
This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), multi-center (when more than 1 hospital or medical school team work on a medical research study), non-randomized, single-arm study of paliperidone ER in participants previously treated with risperidone with poor response. The study will consist of 2 phases: a main phase of 6 months and an extension phase of another 6 months. The total duration of the study will be 12 months. All participants will receive an oral (having to do with the mouth) daily dose of paliperidone ER in flexible dosage (in the range of 3-12 milligram [mg]: 3 mg, 6 mg, 9 mg, or 12 mg) according to Investigator's discretion. Efficacy and safety of participants will primarily be evaluated by Positive and Negative Syndrome Scale (PANSS) and Extrapyramidal Symptoms Rating Scale (ESRS), respectively. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
Drug: Paliperidone Extended Release (ER)
Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 - Main Phase
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Baseline and Week 26
Change From Baseline in PANSS Total Score at Week 52 - Main Phase Plus Extension Phase
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Baseline and Week 52
Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase
Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 26
Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase Plus Extension Phase
Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 52
Change From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13 and 26 - Main Phase
The PANSS positive subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS negative subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).
Time frame: Baseline, Week 4, 8, 13 and 26
Change From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
The PANSS Positive Subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).
Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52
Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 4, 8, 13 and 26 - Main Phase
The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.
Time frame: Baseline, Week 4, 8, 13 and 26
Change From Baseline in PSP Scale Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.
Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52
Change From Baseline in Pittsburg Sleep Quality Index (PSQI) Score at Week 4, 8, 13 and 26 - Main Phase
The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.
Time frame: Baseline, Week 4, 8, 13 and 26
Change From Baseline PSQI Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.
Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52
Number of Participants With Clinical Global Impression-Severity (CGI-S) Score - Main Phase
The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.
Time frame: Baseline, Week 4, 8, 13 and 26
Number of Participants With Clinical Global Impression-Severity (CGI-S) Score - Extension Phase
The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.
Time frame: Week 39 and 52
Percentage of Participants With Treatment Satisfaction - Main Phase
Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.
Time frame: Baseline, Week 4, 8, 13 and 26
Percentage of Participants With Treatment Satisfaction-Main Phase Plus Extension Phase
Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.
Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52
36-Item Short-Form Health Survey (SF-36) Score - Main Phase
The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.
Time frame: Baseline and Week 26
36-Item Short-Form Health Survey (SF-36) Score - Main Phase Plus Extension Phase
The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.
Time frame: Baseline and Week 52
Change From Baseline in Extrapyradimal Symptoms Rating Scale (ESRS) Total Score at Week 4, 8, 13 and 26 - Main Phase
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.
Time frame: Baseline, Week 4, 8, 13 and 26
Change From Baseline in ESRS Total Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.
Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52
| Milestone | Paliperidone Extended Release (ER) |
|---|---|
| Started | 223 |
| Treated | 218 |
| Completed | 174 |
| Not completed | 49 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Adverse event | 7 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Non-compliance to study medication | 5 |
| Withdrew: Selection failure | 2 |
| Withdrew: Inform consent withdrawal | 1 |
| Withdrew: Other | 1 |
| Withdrew: Did not received study medication | 5 |
| Milestone | Paliperidone Extended Release (ER) |
|---|---|
| Started | 174 |
| Completed | 159 |
| Not completed | 15 |
| Withdrew: Extension phase was optional | 15 |
| Milestone | Paliperidone Extended Release (ER) |
|---|---|
| Started | 159 |
| Completed | 156 |
| Not completed | 3 |
| Withdrew: Other | 3 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Paliperidone Extended Release (ER) - Main Phase |
|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 - Main Phase | -22.9 ± 20.1 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Units on a scale | Paliperidone (ER) - Main Phase Plus Extension Phase |
|---|---|
| Baseline | 93.25 ± 11.6 |
| Change at Week 52 | -26.4 ± 17.5 |
Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Percentage of participants | Paliperidone ER-Main Phase |
|---|---|
| Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase | 60.1 (53.2 to 66.7) |
Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
| Percentage of participants | Paliperidone ER-Main Phase Plus Extension Phase |
|---|---|
| Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase Plus Extension Phase | 71.1 (63.4 to 78.0) |
The PANSS positive subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS negative subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).
| Units on a scale | Paliperidone ER-Main Phase |
|---|---|
| Change at Week 4: PANSS positive subscale (n=201) | -3.6 ± 4.8 |
| Change at Week 4: PANSS negative subscale (n=201) | -3.6 ± 4.8 |
| Change at Week 8: PANSS positive subscale (n=191) | -5.0 ± 5.8 |
| Change at Week 8: PANSS negative subscale (n=191) | -5.0 ± 5.8 |
| Change at Week 13: PANSS positive subscale (n=182) | -5.9 ± 5.8 |
| Change at Week 13: PANSS negative subscale (n=182) | -5.9 ± 5.8 |
| Change at Week 26: PANSS positive subscale (n=203) | -5.9 ± 6.2 |
| Change at Week 26: PANSS negative subscale (n=203) | -5.9 ± 6.2 |
The PANSS Positive Subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).
| Units on a scale | Paliperidone ER-Main Phase Plus Extension Phase |
|---|---|
| Baseline: PANSS positive subscale (n=159) | 26.65 ± 6.20 |
| Baseline: PANSS negative subscale (n=159) | 19.25 ± 5.86 |
| Change at Week 4: PANSS positive subscale (n=159) | -3.4 ± 4.4 |
| Change at Week 4: PANSS negative subscale (n=159) | -3.4 ± 4.4 |
| Change at Week 8: PANSS positive subscale (n=159) | -5.4 ± 5.1 |
| Change at Week 8: PANSS negative subscale (n=159) | -5.4 ± 5.1 |
| Change at Week 13: PANSS positive subscale (n=159) | -5.9 ± 5.7 |
| Change at Week 13: PANSS negative subscale (n=159) | -5.9 ± 5.7 |
| Change at Week 26: PANSS positive subscale (n=159) | -6.8 ± 5.5 |
| Change at Week 26: PANSS negative subscale (n=159) | -6.8 ± 5.5 |
| Change at Week 39: PANSS positive subcale (n=152) | -7.3 ± 5.9 |
| Change at Week 39: PANSS negative subscale (n=152) | -7.3 ± 5.9 |
| Change at Week 52: PANSS positive subscale (n=154) | -7.5 ± 6.1 |
| Change at Week 52: PANSS negative subscale (n=154) | -7.5 ± 6.1 |
The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.
| Units on a scale | Paliperidone ER-Main Phase |
|---|---|
| Change at Week 4 (n=201) | 5.7 ± 11.7 |
| Change at Week 8 (n=191) | 8.3 ± 12.8 |
| Change at Week 13 (n=182) | 9.9 ± 14.8 |
| Change at Week 26 (n=204) | 10.4 ± 14.9 |
The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.
| Units on a scale | Paliperidone ER-Main Phase Plus Extension Phase |
|---|---|
| Baseline (n=159) | 45.17 ± 12.84 |
| Change at Week 4 (n=159) | 5.3 ± 9.6 |
| Change at Week 8 (n=159) | 9.0 ± 12.6 |
| Change at Week 13 (n=159) | 9.7 ± 14.4 |
| Change at Week 26 (n=159) | 12.0 ± 12.7 |
| Change at Week 39 (n=151) | 12.6 ± 14.2 |
| Change at Week 52 (n=155) | 14.6 ± 14.9 |
The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.
| Units on a scale | Paliperidone ER-Main Phase |
|---|---|
| Baseline (n=198) | 6.7 ± 4.1 |
| Change at Week 4 (n=174) | -1.0 ± 3.5 |
| Change at Week 8 (n=162) | -1.2 ± 3.5 |
| Change at Week 13 (n=156) | -1.5 ± 3.3 |
| Change at Week 26 (n=174) | -1.4 ± 3.7 |
The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.
| Units on a scale | Paliperidone ER-Main Phase Plus Extension Phase |
|---|---|
| Baseline (n=148) | 6.4 ± 4.1 |
| Change at Week 4 (n=140) | -1.0 ± 3.6 |
| Change at Week 8 (n=136) | -1.3 ± 3.2 |
| Change at Week 13 (137) | -1.5 ± 3.2 |
| Change at Week 26 (n=135) | -1.4 ± 3.5 |
| Change at Week 39 (n=133) | -1.9 ± 3.9 |
| Change at Week 52 (n=133) | -1.9 ± 3.4 |
The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.
| Participants | Paliperidone ER-Main Phase |
|---|---|
| Baseline: Borderline (n=213) | 2 |
| Baseline: Slightly ill (n=213) | 4 |
| Baseline: Moderately ill (n=213) | 52 |
| Baseline: Markedly ill (n=213) | 114 |
| Baseline: Severely ill (n=213) | 40 |
| Baseline: Extremely ill (n=213) | 1 |
| Week 4: Borderline (n=201) | 4 |
| Week 4: Slightly ill (n=201) | 25 |
| Week 4: Moderately ill (n=201) | 87 |
| Week 4: Markedly ill (n=201) | 61 |
| Week 4: Severely ill (n=201) | 24 |
| Week 8: Borderline (n=191) | 5 |
| Week 8: Slightly ill (n=191) | 35 |
| Week 8: Moderately ill (n=191) | 80 |
| Week 8: Markedly ill (n=191) | 56 |
| Week 8: Severely ill (n=191) | 15 |
| Week 8: extremely ill (n=191) | 0 |
| Week 13: Normal, without any disease (n=182) | 2 |
| Week 13: Borderline (n=182) | 7 |
| Week 13: Slightly ill (n=182) | 41 |
| Week 13: Moderately ill (n=182) | 73 |
| Week 13: Markedly ill (n=182) | 47 |
| Week 13: Severly ill (n=182) | 12 |
| Week 26: Normal without any disease (n=204) | 3 |
| Week 26: Borderline (n=204) | 16 |
| Week 26: Slightly ill (n=204) | 48 |
| Week 26: Moderately ill (n=204) | 70 |
| Week 26: Markedely ill (n=204) | 48 |
| Week 26: Severely ill (n=204) | 19 |
The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.
| Participants | Paliperidone ER - Extension Phase |
|---|---|
| Week 39: Normal without any disease (n=152) | 2 |
| Week 39: Borderline (n=152) | 22 |
| Week 39: Slightly ill (n=152) | 41 |
| Week 39: Moderately ill (n=152) | 55 |
| Week 39: Markedely ill (n=152) | 22 |
| Week 39: Severely ill (n=152) | 10 |
| Week 52: Borderline (n=155) | 23 |
| Week 52: Slightly ill (n=155) | 37 |
| Week 52: Moderately ill (n=155) | 58 |
| Week 52: Markedely ill (n=155) | 24 |
| Week 52: Severely ill (n=155) | 10 |
Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.
| Percentage of Participants | Paliperidone ER - Main Phase |
|---|---|
| Baseline: Very good (n=213) | 11.7 |
| Baseline: Good (n=213) | 38.5 |
| Baseline: Moderate (n=213) | 34.3 |
| Baseline: Bad (n=213) | 12.7 |
| Baseline: Very bad (n=213) | 2.8 |
| Week 4: Very good (n=200) | 29.5 |
| Week 4: Good (n=200) | 52.5 |
| Week 4: Moderate (n=200) | 16.5 |
| Week 4: Bad (n=200) | 1.0 |
| Week 4: Very bad (n=200) | 0.5 |
| Week 8: Very good (n=190) | 33.7 |
| Week 8: Good (n=190) | 48.9 |
| Week 8: Moderate (n=190) | 13.7 |
| Week 8: Bad (n=190) | 3.7 |
| Week 13: Very good (n=182) | 37.4 |
| Week 13: Good (n=182) | 46.2 |
| Week 13: Moderate (n=182) | 12.1 |
| Week 13: Bad (n=182) | 3.8 |
| Week 13: Very bad (n=182) | 0.5 |
| Week 26: Very good (n=204) | 36.3 |
| Week 26: Good (n=204) | 46.1 |
| Week 26: Moderate (n=204) | 10.8 |
| Week 26: Bad (n=204) | 4.4 |
| Week 26: Very bad (n=204) | 2.5 |
Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.
| Percentage of participants | Paliperidone ER-Main Phase Plus Extension Phase |
|---|---|
| Baseline: Very good (n=159) | 13.2 |
| Baseline: Good (n=159) | 40.9 |
| Baseline: Moderate (n=159) | 32.1 |
| Baseline: Bad (n=159) | 11.3 |
| Baseline: Very bad (n=159) | 2.5 |
| Week 4: Very good (n=159) | 31.4 |
| Week 4: Good (n=159) | 54.1 |
| Week 4: Moderate (n=159) | 13.8 |
| Week 4: Very bad (n=159) | 0.6 |
| Week 8: Very good (n=159) | 37.1 |
| Week 8: Moderate (n=159) | 11.3 |
| Week 8: Bad (n=159) | 3.1 |
| Week 13: Very good (n=159) | 39.0 |
| Week 13: Good (n=159) | 46.5 |
| Week 13: Moderate (n=159) | 10.1 |
| Week 13: Bad (n=159) | 3.8 |
| Week 13: Very bad (n=159) | 0.6 |
| Week 26: Very good (n=159) | 41.5 |
| Week 26: Good (n=159) | 50.9 |
| Week 26: Moderate (n=159) | 6.9 |
| Week 26: Very bad (n=159) | 0.6 |
| Week 39: Very good (n=152) | 38.8 |
| Week 39: Good (n=152) | 51.3 |
| Week 39: Moderate (n=152) | 7.2 |
| Week 39: Bad (n=152) | 2.0 |
| Week 39: Very bad (n=152) | 0.7 |
| Week 52: Very good (n=155) | 41.3 |
| Week 52: Good (n=155) | 43.2 |
| Week 52: Moderate (n=155) | 12.9 |
| Week 52: Bad (n=155) | 2.6 |
The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.
| Units on a scale | Paliperidone ER- Main Phase |
|---|---|
| Baseline: Physical component summary | 47.9 ± 8.8 |
| Baseline: Mental component summary | 35.9 ± 8.5 |
| Week 26: Physical component summary | 48.4 ± 7.6 |
| Week 26: Mental component summary | 38.3 ± 8.0 |
The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.
| Units on a scale | Paliperidone ER-Main Phase Plus Extension Phase |
|---|---|
| Baseline: Physical component summary | 48.7 ± 8.6 |
| Baseline: Mental component summary | 35.7 ± 8.5 |
| Week 52: Physical component summary | 48.8 ± 7.6 |
| Week 52: Mental component summary | 38.5 ± 8.4 |
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.
| Units on a scale | Paliperidone ER - Main Phase |
|---|---|
| Baseline (n=215) | 1.30 ± 1.99 |
| Change at Week 4 (n=201) | -0.40 ± 1.23 |
| Change at Week 8 (n=189) | -0.45 ± 1.47 |
| Change at Week 13 (n=182) | -0.63 ± 1.76 |
| Change at Week 26 (n=201) | -0.6 ± 1.71 |
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.
| Units on a scale | Paliperidone ER-Main Plus Extension Phase |
|---|---|
| Baseline (n=159) | 1.41 ± 2.14 |
| Change at Week 4 (n=159) | -0.51 ± 1.31 |
| Change at Week 8 (n=159) | -0.49 ± 1.56 |
| Change at Week 13 (n=159) | -0.68 ± 1.85 |
| Change at Week 26 (n=158) | -0.77 ± 1.87 |
| Change at Week 39 (n=151) | -0.81 ± 1.97 |
| Change at Week 52 (n=154) | -0.75 ± 1.94 |
Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone ER - Main Phase | — | 14/215 (6.5%) | 144/215 (67%) |
| Paliperidone ER - Extension Phase | — | 3/159 (1.9%) | 70/159 (44%) |
| Event | Paliperidone ER - Main Phase | Paliperidone ER - Extension Phase |
|---|---|---|
| Psychotic disorder NOSPsychiatric disorders | 5/215 | 0/159 |
| Schizophrenia NOSPsychiatric disorders | 2/215 | 1/159 |
| HospitalizationSurgical and medical procedures | 2/215 | 0/159 |
| Nasal septum deviationRespiratory, thoracic and mediastinal disorders | 0/215 | 1/159 |
| CholecystectomySurgical and medical procedures | 0/215 | 1/159 |
| Pregnancy NOSPregnancy, puerperium and perinatal conditions | 0/215 | 1/159 |
| HypokalemiaMetabolism and nutrition disorders | 1/215 | 0/159 |
| HyponatremiaMetabolism and nutrition disorders | 1/215 | 0/159 |
| Depressed moodPsychiatric disorders | 1/215 | 0/159 |
| Psychomotor agitationPsychiatric disorders | 1/215 | 0/159 |
| Event | Paliperidone ER - Main Phase | Paliperidone ER - Extension Phase |
|---|---|---|
| InsomniaPsychiatric disorders | 32/215 | 14/159 |
| Weight increasedInvestigations | 23/215 | 20/159 |
| AnxietyPsychiatric disorders | 23/215 | 4/159 |
| SomnolenceNervous system disorders | 13/215 | 4/159 |
| HeadacheNervous system disorders | 13/215 | 4/159 |
| AgitationPsychiatric disorders | 12/215 | 0/159 |
| DepressionPsychiatric disorders | 8/215 | 7/159 |
| AkathisiaNervous system disorders | 8/215 | 5/159 |
| Psychomotor hyperactivityNervous system disorders | 8/215 | 0/159 |
| Psychotic disorder NOSPsychiatric disorders | 7/215 | 0/159 |
| Age Continuous(Years) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| Mean | 37.87 ± 11.01 |
| Age, Customized(Participants) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| 18-21 years | 14 |
| 22-29 years | 50 |
| 30-39 years | 51 |
| 40-49 years | 67 |
| 50-60 years | 35 |
| 61-69 years | 1 |
| Sex: Female, Male(Participants) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| Female | 79 |
| Male | 139 |
| Race/Ethnicity, Customized(Participants) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| White/Caucasian | 120 |
| Black | 52 |
| Oriental | 3 |
| Mulatto | 9 |
| Brown | 34 |
| Positive and Negative Syndrome Scale (PANSS) Total Score(Units on a scale) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| Mean | 94.49 ± 12.38 |
| Positive and Negative PANSS Subscales Score(Units on a scale) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| Positive PANSS Subscale Score | 27.37 ± 6.48 |
| Negative PANSS Subscale Score | 19.76 ± 5.79 |
| Personal and Social Performance (PSP) Scale Score(Units on a scale) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| Mean | 44.39 ± 13.11 |
| Pittsburg Sleep Quality Index (PSQI)(Units on a scale) | Paliperidone ER - Main Phase Plus Extension Phase |
|---|---|
| Mean | 6.7 ± 4.1 |
The record gives a start of Feb 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen-Cilag Farmaceutica Ltda. →